Axogen Prices $208.7M Offering to Fund BioCircuit Buyout; Shares Slide 10%
AXGN has more than doubled off its 52-week low of $15.27 on elevated volume (2.0× avg).
Summary
Axogen is acquiring BioCircuit Technologies for $200 million in cash, adding FDA-approved sutureless nerve repair device NerveTape to its portfolio. To fund the deal, the company priced a public offering of 4.91 million shares at $42.50, expecting $208.7 million in gross proceeds. The stock fell 10.54% to $45.46 on the news, reflecting dilution concerns. The transaction is expected to close in Q4 2026, after which Axogen will update full-year guidance. This follows the earlier announcement of the acquisition agreement this morning; the offering terms and market reaction are new details.
Updates
· SEC 424B5 — Underwriters have a 30-day option to buy up to 736,500 additional shares. Net proceeds are estimated at $195.5 million, or $224.8 million if the option is fully exercised.
At the time of this announcement, AXGN was trading at $42.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $15.27 to $52.91. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Benzinga.